Skip to Main Content

Advertisement

Skip Nav Destination

Immuno-oncology

Studies that investigate the immune system, its interactions with tumor cells, and opportunities to enhance the body's natural defenses against cancer

Latest in Immuno-oncology
Matthias Birtel, Ralf-Holger Voss et al.
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T cell CD3 signaling complex. The TCAR ...
Anni Lepland, Alessio Malfanti et al.
Although many studies have explored the depletion of tumor-associated macrophages (TAM) as a therapeutic strategy for solid tumors, currently available compounds suffer from poor efficacy and dose-limiting side effects. Here, we developed a novel TAM-depleting agent (“OximUNO”) that specifically targets CD206+ TAMs and ...
Richard A Harbison, Rajeev Kumar Pandey et al.
Metabolic features of the tumor microenvironment (TME) antagonize anti-tumor immunity. We hypothesized that T cell infiltrated tumors with a known antigen should exhibit superior clinical outcomes, though some fare worse given unfavorable metabolic features leveraging T cell-infiltrated (Thi), human papillomavirus-related ...
Aryana Javaheri, Yonina Bykov et al.
Avulaviruses represent a diverse subfamily of non-segmented negative strand RNA viruses infecting avian species worldwide. To date, 22 different serotypes have been identified in a variety of avian hosts, including wild and domestic birds. APMV-1, also known as Newcastle disease virus (NDV), is the only avulavirus that ...
Jamila Kacher, Olivier Manches et al.
In neuroblastoma (NB), MYCN amplification is associated with sparse immune infiltrate, and poor prognosis. Dendritic cells (DCs) are crucial immune sentinels but their involvement in NB pathogenesis is poorly understood. We observed that the migration of monocytes, MDC and PDC induced by MYCN non-amplified NB supernatants ...
Galaxia M. Rodriguez, Kristianne J.C. Galpin et al.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given ...
Ainhoa Perez-Diez, Xiangdong Liu et al.
Tumor-associated macrophages (TAM) promote tumor survival, angiogenesis, and metastases. Although they express MHC class II molecules, little is known about their ability to present tumor antigens to tumor-infiltrating CD4 T cells, and the consequences of such presentation. To answer these questions, we used a C57/BL10 ...
Anne W.J. Martens, Joanne M. Rietveld et al.
T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. B-cell maturation antigen (BCMA) exhibits high expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition of γ-secretase. BCMA is considered a validated target in multiple ...
Paul A. Hamlin, Vasile Musteata et al.
MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal inactivation. This study evaluated MT-3724 in patients with ...
Ana M. Metelo, Agnieszka Jozwik et al.
Multiple myeloma remains an incurable plasma cell malignancy despite the rapidly evolving treatment landscape. Chimeric antigen receptor T cells targeted against BCMA have recently shown great promise in relapsed refractory multiple myeloma; however, all patients ultimately still progress from their disease. Lack of CAR ...
Close Modal

or Create an Account

Close Modal
Close Modal